Perrigo vitamin settlement
This article was originally published in The Tan Sheet
Executive Summary
Private labeler will record $7.8 mil. pre-tax gain in third quarter ending March 31 stemming from settlement with unidentified defendants in vitamin price-fixing litigation. "Effect on net income will be approximately $5 mil.," firm says in Feb. 1 SEC filing. Case against remaining price-fixing defendants is proceeding, notes Allegan, Mich.-based firm, which previously reported vitamin litigation settlement payments of $995,000 and $4.2 mil. for FY 2001 and 2000, respectively...
You may also be interested in...
Perrigo vitamin settlement
Private labeler will record $20.1 mil. pre-tax gain in fiscal fourth quarter ending June 30 stemming from settlements in vitamin price-fixing litigation. Settlement proceeds, which were received May 17, will boost net income by approximately $12.9 mil. Perrigo recorded $7.8 mil. pre-tax gain in Q3 following similar settlements (1"The Tan Sheet" Feb. 18, 2002, p. 14)...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.